Ehrlich G E, Wortham G F
Clin Pharmacol Ther. 1975 Apr;17(4):467-8. doi: 10.1002/cpt1975174467.
In a clinical study of the new nonsteroidal anti-inflammatory drug tolmetin, the urines of 5 patients reacted positively when tested for protein by the standard sulfosalicylic acid method. Pseudoproteinuria, due to the precipitation by acid of the major metabolite of tolmetin, was suspected. The urines were subsequently tested for protein by the following alternate methods: solubility of acid precipitate test, heat coagulation test, Upjohn modification of the sulfosalicylic acid test, biuret test, Albustix, and electrophoresis. All were negative for protein. These results confirmed that the reactions with the sulfosalicylic acid test did not indicate true proteinuria but pseudoproteinuria. It is suggested that patients who receive tolmetin be tested for proteinuria by methods other than those involving acid precipitation.
在一项关于新型非甾体抗炎药托美丁的临床研究中,5名患者的尿液采用标准磺基水杨酸法检测蛋白质时呈阳性反应。怀疑是由于托美丁主要代谢产物被酸沉淀导致的假性蛋白尿。随后采用以下替代方法检测尿液中的蛋白质:酸沉淀溶解度试验、热凝固试验、磺基水杨酸试验的Upjohn改良法、双缩脲试验、尿蛋白试纸条法以及电泳法。所有检测结果均为蛋白质阴性。这些结果证实,磺基水杨酸试验的反应并不表明存在真性蛋白尿,而是假性蛋白尿。建议对接受托美丁治疗的患者采用不涉及酸沉淀的方法检测蛋白尿。